サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1550793

世界の臍帯血・臍帯組織バンク産業：市場規模、分類、予測 (2024年)

Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024
出版日: | 発行: BioInformant | ページ情報: 英文 296 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.16円
世界の臍帯血・臍帯組織バンク産業：市場規模、分類、予測 (2024年)
出版日: 2024年09月09日
発行: BioInformant
ページ情報: 英文 296 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

エグゼクティブサマリー

臍帯血由来の造血幹細胞 (HSC) を用いた最初の移植は1988年10月に行われました。それ以来、臍帯血由来の造血幹細胞や前駆細胞の調査において大きな進歩がありました。現在までに、世界中で4万件以上の臍帯血移植 (UCBT) が行われ、血液疾患、代謝疾患、免疫疾患、腫瘍性疾患、神経疾患など、さまざまな疾患の治療が行われています。現在、公共臍帯血バンクは80万本以上を保管し、民間バンクは全世界で810万単位本を保管しています。

臍帯血保存は1990年代初めに商業サービスとして始まりましたが、臍帯組織保存が商業的に利用できるようになったのは2008年からで、台湾のHealthBanks Biotech Company Ltd.が主要企業となっています。香港のHealthBabyとCryolifeも2009年にサービスを開始しました。米国では、2010年7月にCord Blood Registry (CBR) が非公開会社として初めて臍帯組織保管サービスを開始しました。現在では、米国のほぼすべての臍帯血バンクと、世界の臍帯血バンクの約3分の1が臍帯組織保管サービスを提供しています。

LifebankUSAは、2006年に米国における胎盤血保存のパイオニアとなり、2011年に胎盤組織保存を導入しました。Americord Registryは2017年9月に胎盤組織バンクを導入しました。国際的には、現在いくつかの臍帯血バンクが胎盤血と胎盤組織の保存を提供しています。歯髄幹細胞など、他の幹細胞供給源に多角化しているところもあります。例えば、ラテンアメリカ最大の臍帯血バンクのコンソリデーターであるCryoholdcoが運営するDentCellは、歯髄幹細胞に焦点を当てています。さらに、いくつかの臍帯血バンクは、脂肪由来幹細胞の保存にも進出しています。

近年、臍帯血業界では記録的なレベルの合併・買収 (M&A) が行われています。臍帯血市場は現在、Global Cord Blood Corporation (GCBC)、Cord Blood Registry (CooperSurgical所有)、ViaCord、Cryo-Cell International、Cordlife Group、VCANBIO Cell &Gene Engineering Corporation、Lifecell International、Cryoholdco、Medipostなど、一握りの大手臍帯血バンク事業者によって支配されています。2000年代初頭の業界の急成長を考えると、この統合は注目に値します。米国、欧州、アジア、ラテンアメリカで大規模な市場再編が生じています：

  • PBK FamiCordは、最大の競合であるVita34との合併や、2019年に破産したCryo-Save AGの資産買収を含め、欧州市場の大半を獲得しました。
  • CooperSurgicalは、米国内で生殖医療、新生児幹細胞、遺伝子サービスを統合し、少なくとも110万本を管理しています。
  • Cryoholdcoは、ラテンアメリカ全域で幹細胞バンク資産を蓄積しており、メキシコに4ヶ所、コロンビアに2ヶ所、ブラジルに2ヶ所、ペルーに1ヶ所、合計30万本と推定されます。
  • Sampower Groupは、Global Cord Blood Corporationをはじめ、東南アジア全域で120万本以上の資産を所有し、アジア市場を独占しています。
  • インドは14億人もの急成長中の人口を抱え (世界の総人口 (78億人) の約36%)、中国に匹敵する規模となっています。LifeCell Internationalは、インドを代表する幹細胞バンクで、32万本以上を保管しています。

臍帯血業界はまた、臍帯血、臍帯組織、胎盤血・組織、羊水を含む周産期組織への活用においても大きな進歩を遂げています。このため、これらの生体物質の保管サービスが急増しています。

多くの臍帯血バンクは、提供するサービスを拡大しています：

  • 生殖・生殖補助医療サービス
  • 出生前・出生後の遺伝子検査
  • 細胞治療製品の開発

臍帯血・臍帯組織市場は、以下のようなセグメントで構成されています：

  • 1. 保存 (凍結保存)：臍帯血の採取・処理・長期保存契約から収益が得られます。最近、投資会社がこの市場に参入し、臍帯血・組織バンクの株式を取得しています。
  • 2. 移植医療：白血病や鎌状赤血球症などの疾患の治療に臍帯血を使用する市場は堅調です。これまでに4万件以上の臍帯血移植が行われ、臍帯血由来幹細胞による治療が承認された疾患は80種類以上にのぼります。
  • 3. 再生医療：再生医療における臍帯血・組織の使用に関する調査は拡大しています。臨床試験では、脳性麻痺、自閉症スペクトラム障害、難聴などの神経疾患の治療が検討されています。現在Catalentが所有するRheinCell Therapeuticsは、臍帯血由来iPSCの製造に関するGMP認証を取得しました。FDAは2023年4月、世界初の拡大臍帯血細胞療法Omisirgeを承認しました。
  • 4. 研究用供給製品：このセグメントには細胞・組織・試薬・キットが含まれます。Lonza、STEMCELL Technologies、AllCellsなどの主要な市場リーダーが現在、研究目的の臍帯血製品を提供しています。

当レポートは以下の情報を含む包括的な調査を提供します：

  • 1. 世界の公共・民間バンクに凍結保存されている臍帯血・組織の本数。
  • 2. 臍帯血細胞を用いて世界的に行われた造血幹細胞移植の件数。
  • 3. 再生医療臨床試験における臍帯血細胞の利用状況。
  • 4. 2005年以降の造血幹細胞移植における臍帯血利用の減少。
  • 5. 公共臍帯血バンクの財政的持続可能性に影響を及ぼす新たな技術。
  • 6. 臍帯血由来コンパニオン製品の将来展望。
  • 7. 臍帯血・組織バンク市場の発展状況。
  • 8. 臍帯血バンクによるサービスの拡大と拡張。
  • 9. 公共・民間臍帯血バンクの経済モデルとコスト分析。
  • 10. 民間バンクにおける処理と保存の利益率と価格設定。
  • 11. 米国・欧州における臍帯血単位あたりの料金。
  • 12. 移植医療における臍帯血由来造血幹細胞の適応。
  • 13. 再生医療における臍帯血由来MSCの対象疾患。
  • 14. 臍帯血処理技術とそれを提供する有力なマーケットリーダー。
  • 15. 臨床試験、発表された科学論文、および臍帯血研究のための資金。
  • 16. 臍帯血、臍帯組織、胎盤製品の特許。
  • 17. さまざまな臍帯血レジストリからの移植データ。

当レポートで扱う主な質問は以下の通りです：

  • 1. 民間臍帯血バンクの財務的安定性を向上させるための戦略。
  • 2. 公共臍帯血バンクの財務的安定性を向上させるための戦略。
  • 3. 臍帯血・組織から開発されるコンパニオン製品。
  • 4. 臍帯血の処理と保存にかかる費用。
  • 5. 凍結保存された臍帯血ユニットが放出されたときの市場価値。
  • 6. 公共臍帯血バンクが一般的に被る財務的損失。
  • 7. 民間臍帯血バンクの純利益率。
  • 8. 民間バンクにおける処理・保管サービスの価格設定。
  • 9. 米国・欧州における臍帯血1本あたりの料金。
  • 10. 主要バンクの臍帯血販売収入。
  • 11. 臍帯血・組織バンクの認定制度。
  • 12. 臍帯血処理技術の比較メリット。
  • 13. 移植における臍帯血利用を増加させるための戦略。
  • 14. 移植に望ましいTNC数。
  • 15. 臍帯血・臍帯組織を用いた臨床試験の登録件数。
  • 16. 臍帯血の生体外拡張を研究している臨床試験と最近の製品承認。
  • 17. 適合および不一致の臍帯血移植の年間件数。
  • 18. 骨髄移植および末梢血移植と比較した臍帯血移植のシェア。
  • 19. 適合する同種臍帯血ユニットが見つかる可能性：民族別。
  • 20. 臍帯血提供の上位国。
  • 21. 臨床試験において臍帯血や組織由来MSCが標的とする疾患。
  • 22. 臍帯血由来細胞を研究している臨床試験：地域別・試験の種類別、相別、資金別の内訳。
  • 23. 臍帯組織由来細胞を研究している臨床試験の内訳。
  • 24. 臍帯血・臍帯組織・胎盤に関する特許：現在の取得率および主要な管轄区域。
  • 25. 周産期幹細胞特許の主要な発明者・出願人・所有者。
  • 26. 世界の公共・民間バンクが保管する本数。
  • 27. 主要な臍帯血バンクの保管本数：地域別。
  • 28. 臍帯血・組織バンクと治療用途の市場規模。

この世界戦略報告書は、臍帯血・組織バンク市場を徹底的に分析し、現在の動向、将来予測、業界の主要企業に関する洞察を提供します。調査に過度な時間を費やすことなく市場の包括的な理解を求める方にとって、不可欠な資料です。

目次

第1章 調査概要

第2章 臍帯血バンク：概要

  • 臍帯血サンプルの成分
  • 臍帯血バンク
    • 公立臍帯血バンク
    • 民間臍帯血バンク
    • ハイブリッド臍帯血バンク
    • クロスオーバー臍帯血バンク
    • コミュニティ臍帯血バンク
  • 米国の公立・民間・ハイブリッド臍帯血バンクの割合

第3章 臍帯血バンクの認定

  • AABB(American Association of Blood Banks)
  • FACT (Foundation for the Accreditation of Cellular Therapy)
  • 臍帯血バンクのFDA登録
  • HTA (Human Tissue Authority) (英国)
  • TGA (Therapeutic Goods Act) (オーストラリア)
  • International NetCord Foundation

第4章 臍帯血・臍帯組織・胎盤の特許情勢

  • 臍帯血幹細胞の特許
    • 臍帯血特許の法的地位
    • 臍帯血特許の出願件数：年度別
    • 臍帯血特許の出願件数：管轄別
    • 臍帯血特許の出願者上位10社
    • 臍帯血特許の発明者上位10社
    • 臍帯血特許の保有者上位20社
  • 臍帯血由来MSCに関する特許
    • UCB由来MSC特許の法的地位
    • UCB由来MSC特許の出願件数：年度別
    • UCB由来MSC特許の出願件数：管轄別
    • UCB由来MSC特許の出願人上位10社
    • UCB由来MSC特許の発明者上位10社
    • UCB由来MSC特許の所有者上位20社
  • 臍帯組織に関する特許
    • 臍帯組織特許の法的地位
    • 臍帯組織特許の出願件数：年度別
    • 臍帯組織特許の出願件数：管轄別
    • 臍帯組織特許の出願者上位10社
    • 臍帯組織特許の発明者上位10社
    • 臍帯組織特許の保有者上位20社
  • 胎盤に関する特許
    • 胎盤組織特許の法的地位
    • 胎盤組織特許の出願件数：年度別 (2000～2022年)
    • 胎盤組織特許の出願件数：管轄別
    • 胎盤組織特許の出願者上位10社
    • 胎盤組織特許の発明者上位10社
    • 胎盤組織特許の保有者上位20社
  • 臍帯血増殖に関する特許
    • 臍帯血増殖特許の出願件数：年度別
    • 臍帯血増殖特許の出願件数の管轄地域上位10地域
    • 臍帯血増殖特許の法的地位
    • 臍帯血増殖特許の発明者上位10社
    • 臍帯血増殖特許の保有者上位20社
    • 臍帯血増殖に関する特許出願件数 (年別)
    • CB拡張特許の管轄地域上位10地域
    • 臍帯血増殖特許の法的地位
    • 臍帯血増殖特許のトップ10発明者
    • 臍帯血増殖特許の保有者上位20社

第5章 臍帯血研究の刊行物

  • 臍帯血に関する論文数
  • 臍帯組織に関する科学刊行物
  • 胎盤組織に関する科学刊行物
  • UCB細胞増殖に関する科学刊行物

第6章 臨床試験：臍帯血・臍帯組織・胎盤・臍帯血増殖

  • 臍帯血幹細胞を用いた臨床試験
    • 臍帯血幹細胞を用いた臨床試験数：地域別
    • 臍帯血の臨床試験の件数：研究の種類別
    • 臨床試験の件数：研究段階別
    • 臨床試験の件数：資金提供者の種類別
    • 現在募集中の臍帯血臨床試験の対象疾患
    • 臍帯血臨床試験に参加している企業
  • 臍帯組織を用いた臨床試験
    • 臍帯組織を用いた臨床試験数：地域別
    • 臍帯組織の臨床試験の件数：研究段階別
    • 臍帯組織の臨床試験の件数：資金提供者別
    • 臍帯組織の臨床試験における商業団体
  • 胎盤組織幹細胞を用いた臨床試験
    • 胎盤組織の臨床試験の件数：研究段階別
  • 臍帯血増殖に関する臨床試験
    • 臍帯血細胞を用いた臨床試験の主な参加者

第7章 臍帯血処理技術：概要

  • 臍帯血幹細胞の分離プロセス
    • PrepaCyte CB
    • Hetastarch (HES)
    • AutoXpress (AXP)
    • SEPAX
    • プラズマ除去法 (MaxCellプロセス)
    • 密度勾配法
  • 異なる処理方法の利点の比較
    • 早期段階HSCの回収：技術別
    • 臍帯血からの中期段階HSC (CD34+/CD133+) 回収：技術別
    • 臍帯血からの造血幹細胞の後期回収：技術別
    • HSC (CD45+) 回収
  • 好中球移植の日数：技術別
  • 臍帯血処理に使用される抗凝固剤
    • 抗凝固剤の種類と細胞回収量
  • 細胞回収率：サンプルサイズ別
  • TNCの生存率：輸送時間別・抗凝固剤の種類別
  • 臍帯血細胞の凍結保存
    • 理想的な凍結防止剤
  • 臍帯組織 (UCT) のバイオプロセス
  • 臍帯血増殖技術
    • Notch Ligand Delta 1
    • MSCとの共培養
    • 銅キレート化
    • ニコチンアミド
    • StemRegenin 1 (SR1)
    • UM171　
    • ホーミングの強化
    • プロスタグランジンE2　
    • 補体3a (C3a)
    • フコシル化

第8章 世界各地で入手可能な臍帯血ユニット：概要

  • 同種CBUドナー人数と、世界各国で利用可能なCBUの数
  • 世界各国の非血縁CBドナー数と、CBUのHLAタイピング (2021年)
  • 世界各国に出荷される非血縁BM・PB・CB造血幹細胞の数量
  • 世界の臍帯血造血幹細胞の交換状況

第9章 臍帯血移植の適応

  • 臍帯血幹細胞の有益な特性
    • UCBCの造血特性
    • UCBCの免疫特性
    • UCBTレシピエントにおけるHLA不一致の影響
  • UCB移植の悪性度
  • UCB移植で治療できる非悪性疾患
  • 再生医療としてUCBを用いて研究されている疾患

第10章 臍帯血：移植医療としての活用

  • CB・BM・PB幹細胞移植の件数の比較
  • 臍帯血幹細胞移植：地域別 (1999～2021年)
    • 米国における造血幹細胞移植 (HSCT) の適応
    • 米国における臍帯血HLAマッチングと民族的背景
    • 臍帯血移植の費用
    • HCT後1年間の合併症

第11章 再生医療における臍帯血幹細胞

  • 自閉症
  • 脳性麻痺
  • アルツハイマー病
  • 糖尿病
  • 心臓病
  • 多発性硬化症
  • 脳卒中

第12章 市場分析

  • 臍帯血バンキングサービス市場
    • 臍帯血バンキングサービス市場の収益シェア：地域別
    • 公共/民間臍帯血バンキングサービス市場
    • 世界の臍帯血・臍帯組織サービスの市場シェア
  • 世界の治療用途向け臍帯血・臍帯組織市場
    • CB移植および再生医療用CBの市場シェア
    • 臍帯血・臍帯組織の市場シェア：適応症別
  • 世界の臍帯組織 (UCT) 市場

第13章 主要な臍帯血バンクと関連団体：概要

  • AllCells
  • AlphaCord
  • Americord Registry, Inc.
  • Angiocrine Bioscience
  • Anja Health Personalized Cord Blood Banking
  • Anthony Nolan
  • Baylx, Inc.
  • Be The Match
  • Biocell Center
  • BioEden
  • BioIntegrate, LLC
  • Bloodworks Northwest
  • California Umbilical Cord Collection Program
  • Carolinas Cord Blood Bank (CCBB)
  • Celaid Therapeutics
  • Celebration Stem Cell Centre (CSCC)
  • Cell Care
  • Cellenkos, Inc.
  • Cells4Life Group LLP
  • CellSave Arabia
  • Celularity, Inc.
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • CHOC Blood Bank
  • Cleveland Cord Blood Center
  • ClinImmune Cell and Gene Therapy
  • Cord Blood Bank of Arkansas (CBBA)
  • Cord Blood Center Group
  • Cord Blood Registry (CBR)
  • Cord for Life
  • CordLife Group, Ltd.
  • CordVida
  • Crioestaminal
  • Cryo-Cell International, Inc.
  • CryoCyte, LLC
  • CryoHoldco LATAM
  • Cryopoint
  • Cryoviva Biotech Pvt., Ltd.
  • DKMS gGMBH
  • Duke University School of Medicine
  • European Society for Blood and Bone Marrow Transplantation (EBMT)
  • Ever Supreme Bio Technology, Co., Ltd.
  • ExCellThera
  • FamiCord Group
  • Fate Therapeutics, Inc.
  • Future Health
  • Gamida Cell
  • GeneCell
  • Global Cord Blood Corporation (GCBC)
  • Glycostem Therapeutics
  • Hawaii Cord Blood Bank
  • HealthBaby
  • HealthBanksUSA
  • HEMAFUND
  • Hemogenyx Pharmaceuticals
  • IMMUNIQUE
  • Insception LifeBank
  • JP McCarthy Cord Stem Cell Bank
  • Kangstem Biotech, Co., Ltd.
  • LifebankUSA
  • LifeCell International Pvt. Ltd.
  • Life Line Stem Cell
  • LifeSouth Cord Blood Bank
  • Magenta Therapeutics
  • Maze Cord Blood
  • Medipost, Co., Ltd.
  • Mesoblast, Ltd.
  • MD Anderson Cord Blood Bank
  • Mesoblast, Ltd.
  • MiracleCord, Inc.
  • Mononuclear Therapeutics, Ltd.
  • New England Cord Blood Bank, Inc.
  • New York Blood Center
  • OrganaBio
  • PacifiCord
  • Plasticell Ltd.
  • ReeLabs Pvt. Ltd.
  • Restem, LLC
  • San Diego Cord Blood Bank
  • Saneron CCEL Therapeutics, Inc.
  • U-CORD-CELL Program
  • SERT-CELL Program
  • SmartCells
  • SSM Cardinal Glennon Children's Medical Center
  • ALLOCORD
  • Stembanc, Inc.
  • Popular Packages from Stembanc
  • Stem Cell Cryobank, Inc.
  • StemCyte, Inc.
  • Throne Biotechnologies, Inc.
  • Transcell Biolife
  • Upstate Cord Blood Bank
  • ViaCord
  • Versity, Inc.
  • Vita 34 AG
  • Vitalant Clinical Services
  • World Marrow Donor Association (WMDA)
  • Worldwide Network for Blood & Marrow Transplantation (WBMT)

図の索引

表の索引

目次

EXECUTIVE SUMMARY

The first transplant using cord blood-derived hematopoietic stem cells (HSCs) occurred in October 1988. Since then, significant advancements have been made in researching umbilical cord blood-derived hematopoietic and progenitor cells. To date, over 40,000 umbilical cord blood transplants (UCBTs) have been performed worldwide, treating a variety of conditions, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. Public cord blood banks now store more than 800,000 units, while private banks house over 8.1 million units globally.

Cord blood storage began as a commercial service in the early 1990s, but cord tissue storage only became available commercially in 2008, with HealthBanks Biotech Company Ltd. in Taiwan leading the way. Hong Kong's HealthBaby and Cryolife also introduced the service in 2009. In the U.S., Cord Blood Registry (CBR) was the first private company to offer cord tissue storage in July 2010. Today, nearly all U.S. cord blood banks and about one-third of global cord blood banks provide cord tissue storage.

LifebankUSA pioneered placental blood storage in the U.S. in 2006 and introduced placental tissue storage in 2011. Americord Registry followed with placental tissue banking in September 2017. Internationally, several cord blood banks now offer placental blood and tissue storage. Some have diversified into other stem cell sources, such as dental pulp stem cells. For example, DentCell, managed by Cryoholdco, Latin America's largest cord blood banking consolidator, focuses on dental pulp stem cells. Additionally, a few cord blood banks are expanding into adipose-derived stem cell storage.

Recent years have seen record levels of merger and acquisition (M&A) activity in the cord blood industry. The market is now predominantly controlled by a handful of large cord blood banking operators, including Global Cord Blood Corporation (GCBC), Cord Blood Registry (owned by CooperSurgical), ViaCord, Cryo-Cell International, Cordlife Group, VCANBIO Cell & Gene Engineering Corporation, Lifecell International, Cryoholdco, and Medipost. This consolidation is notable given the rapid growth of the industry in the early 2000s. Significant consolidation has occurred in the U.S., Europe, Asia, and Latin America:

  • PBK FamiCord has acquired most of the European market, including merging with it largest competitor Vita34 and acquiring assets from Cryo-Save AG's 2019 bankruptcy.
  • CooperSurgical has consolidated reproductive, newborn stem cell, and genetic services within the U.S., managing at least 1.1 million units.
  • Cryoholdco has amassed stem cell banking assets across Latin America, including four in Mexico, two in Colombia, two in Brazil, and one in Peru, totaling an estimated 300,000 units.
  • Sanpower Group dominates the Asian market through its ownership of Global Cord Blood Corporation and other assets across Southeast Asia, controlling over 1.2 million units.
  • India, with its burgeoning population of 1.4 billion, rivals China in size, making up approximately 36% of the world's 7.8 billion people. LifeCell International is the leading stem cell bank in India, storing over 320,000 units.

The cord blood industry has also seen substantial advancements in perinatal tissue applications, including umbilical cord blood, umbilical cord tissue, placental blood and tissue, and amniotic fluid. This has led to a proliferation of storage services for these biomaterials.

Many cord blood banks have expanded their offerings to include:

  • Reproductive and assisted fertility services
  • Pre-and post-natal genetic testing
  • Cell therapy product development

The Cord Blood and Tissue Market is composed of several segments, including:

  • 1. Storage (Cryopreservation): Revenue comes from cord blood collection, processing, and long-term storage contracts. Investment firms have recently entered this market, acquiring stakes in cord blood and tissue banks.
  • 2. Transplantation Medicine: There is a robust market for cord blood use in treating diseases such as leukemia and sickle cell disease. Over 40,000 UCB transplants have been performed, with more than 80 medical conditions approved for treatment with cord blood-derived stem cells.
  • 3. Regenerative Medicine: Research into the use of cord blood and tissue in regenerative medicine is expanding. Clinical trials are exploring treatments for neurological disorders like cerebral palsy, autism spectrum disorder, and hearing loss. RheinCell Therapeutics, now owned by Catalent, has achieved GMP certification for manufacturing cord blood-derived iPSCs. The FDA approved the world's first expanded cord blood cell therapy, Omisirge, in April 2023.
  • 4. Research Supply Products: This segment includes cells, tissues, reagents, and kits. Major market leaders such as Lonza, STEMCELL Technologies, and AllCells are now offering cord blood products for research purposes.

This report provides a comprehensive analysis, including:

  • 1. The number of cord blood and tissue units cryopreserved in public and private banks worldwide.
  • 2. The number of hematopoietic stem cell transplants performed globally using cord blood cells.
  • 3. The use of cord blood cells in regenerative medicine clinical trials.
  • 4. The decline in cord blood utilization for HSCT since 2005.
  • 5. Emerging technologies influencing public cord blood banks' financial sustainability.
  • 6. Future prospects for companion products derived from cord blood.
  • 7. The evolving landscape of the cord blood and tissue banking market.
  • 8. Expansion and extension of services by cord blood banks.
  • 9. Economic models and cost analyses for public and private cord blood banks.
  • 10. Profit margins and pricing for processing and storage in private banks.
  • 11. Rates per cord blood unit in the U.S. and Europe.
  • 12. Indications for cord blood-derived HSCs in transplantation medicine.
  • 13. Diseases targeted by cord blood-derived MSCs in regenerative medicine.
  • 14. Cord blood processing technologies and the dominant market leaders offering them.
  • 15. Clinical trials, published scientific papers, and funding for cord blood research.
  • 16. Patents for cord blood, cord tissue, and placental products.
  • 17. Transplantation data from various cord blood registries.

Key questions addressed in this market report include:

  • 1. Strategies to improve the financial stability of private cord blood banks.
  • 2. Strategies to improve the financial stability of public cord blood banks.
  • 3. Companion products being developed from cord blood and tissue.
  • 4. Costs for processing and storing cord blood.
  • 5. Market value of cryopreserved cord blood units upon release.
  • 6. Financial losses commonly incurred by public cord blood banks.
  • 7. Net profit margins for private cord blood banks.
  • 8. Pricing for processing and storage services in private banks.
  • 9. Rates per cord blood unit in the U.S. and Europe.
  • 10. Revenues from cord blood sales for major banks.
  • 11. Accreditation systems for cord blood and tissue banks.
  • 12. Comparative merits of cord blood processing technologies.
  • 13. Strategies to increase cord blood utilization in transplantation.
  • 14. Preferred TNC counts for transplantation.
  • 15. Number of registered clinical trials using cord blood and cord tissue.
  • 16. Clinical trials studying ex vivo expansion of cord blood and a recent product approval.
  • 17. Annual number of matching and mismatching cord blood transplantations.
  • 18. Share of cord blood transplants compared to bone marrow and peripheral blood transplants.
  • 19. Likelihood of finding matching allogeneic cord blood units by ethnicity.
  • 20. Top countries for cord blood donations.
  • 21. Diseases targeted by cord blood and tissue-derived MSCs in clinical trials.
  • 22. Breakdown of clinical trials investigating cord blood-derived cells by geography, study type, phase, and funding.
  • 23. Breakdown of trials exploring cord tissue-derived cells.
  • 24. Current patent rates and leading jurisdictions for cord blood, cord tissue, and placental patents.
  • 25. Leading inventors, applicants, and owners of perinatal stem cell patents.
  • 26. Number of units stored by public and private banks worldwide.
  • 27. Leading cord blood banks by region and storage volume.
  • 28. Market sizes for cord blood and tissue banking and therapeutic applications.

This global strategic report offers a thorough analysis of the cord blood and tissue banking market, providing insights into current trends, future projections, and key players in the industry. It is an essential resource for those seeking a comprehensive understanding of the market without investing excessive time in research.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CORD BLOOD BANKS: AN OVERVIEW

  • 2.1. Components of a Cord Blood Sample
  • 2.2. Cord Blood Banks
    • 2.2.1. Public Cord Blood Bank
      • 2.2.1.1. Public Cord Blood Banks in the U.S.
      • 2.2.1.2. Public Cord Blood Banks in Major European Countries
      • 2.2.1.3. Economic Model of Public Cord Blood Banks
      • 2.2.1.4. Cost Analysis for Public Cord Blood Banks
      • 2.2.1.5. Relationship between Costs and Release Rates
    • 2.2.2. Private Cord Blood Banks
      • 2.2.2.1. Private Cord Blood Banks in the U.S
      • 2.2.2.2. Top Seven U.S. Private Cord Blood Banks by Size of Inventory
      • 2.2.2.3. Comparison of Top Three U.S. Private Cord Blood Banks
      • 2.2.2.4. Pricing for Processing and Storage of CB in Private Banks
      • 2.2.2.5. Major U.S. Private Cord Blood Banks by their Special Services
      • 2.2.2.6. Key Factors to be Considered by Parents before Choosing a Private Bank
      • 2.2.2.7. World's Top Ten Private Cord Blood Banks by Inventory
      • 2.2.2.8. Special Features of World's Largest Private Cord Blood Banks
      • 2.2.2.9. Cost Analysis for Private Cord Blood Banks
        • 2.2.2.9.1. Economic Model of Private Cord Blood Banks
        • 2.2.2.9.2. Profit Margins of Four Global Private Cord Blood Banks
    • 2.2.3. Hybrid Cord Blood Banks
    • 2.2.4. Cross-over Cord Blood Bank
    • 2.2.5. Community Cord Blood Bank
  • 2.3. Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.

3. CORD BLOOD BANK ACCREDITATIONS

  • 3.1. American Association of Blood Banks (AABB)
    • 3.1.1. AABB Accreditation Phases and Expectations
  • 3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
    • 3.2.1. FACT Standards
    • 3.2.2. FACT Accreditation Process
  • 3.3. FDA Registration of Cord Blood Banks
    • 3.3.1. FDA Biologics License Application (BLA) for Cord Blood
    • 3.3.2. Investigation New Drug (IND) for Cord Blood
  • 3.4. Human Tissue Authority (HTA) in U.K.
  • 3.5. Therapeutic Goods Act (TGA) in Australia
  • 3.6. International NetCord Foundation

4. PATENT LANDSCAPE OF UMBILICALCORD BLOOD, CORD TISSUE & PLACENTA

  • 4.1. Umbilical Cord Blood Stem Cell Patents
    • 4.1.1. Legal Status of Cord Blood Patents
    • 4.1.2. Umbilical Cord Blood Patent Applications by Year
    • 4.1.3. Umbilical Cord Blood Patent Application by Jurisdiction
    • 4.1.4. Top Ten Umbilical Cord Blood Patent Applicants
    • 4.1.5. Top Ten Inventors of Umbilical Cord Blood Patents
    • 4.1.6. Top Twenty Owners of Umbilical Cord Blood Patents
  • 4.2. Patents on Umbilical Cord Blood-Derived MSCs
    • 4.2.1. Legal Status of UCB-Derived MSC Patents
    • 4.2.2. UCB-Derived MSC Patent Applications by Year
    • 4.2.3. UCB-Derived MSC Patent Application by Jurisdiction
    • 4.2.4. Top Ten UCB-Derived MSC Patent Applicants
    • 4.2.5. Top Ten Inventors of UCB-Derived MSC Patents
    • 4.2.6. Top Twenty Owners of UCB-Derived MSC Patents
  • 4.3. Patents on Cord Tissue
    • 4.3.1. Legal Status of Cord Tissue Patents
    • 4.3.2. Cord Tissue Patent Applications by Year
    • 4.3.3. Cord Tissue Patent Application by Jurisdiction
    • 4.3.4. Top Ten Cord Tissue Patent Applicants
    • 4.3.5. Top Ten Inventors of Cord Tissue Patents
    • 4.3.6. Top Twenty Owners of Cord Tissue Patents
  • 4.4. Patents on Placenta
    • 4.4.1. Leading Placenta-based Patent Applicants
    • 4.4.2. Placental Tissue Patent Applications by Year, 2000-2022
    • 4.4.3. Top Ten Jurisdictions of Placental Tissue Patents
    • 4.4.4. Top Ten Inventors of Placental Tissue Patents
    • 4.4.5. Top Twenty Owners of Placental Tissue Patents
    • 4.4.6. Legal Status of Placental Tissue Patents
  • 4.5. Patents on Cord Blood Expansion
    • 4.5.1. Number of Cord Blood Expansion Patent Applications by Year
    • 4.5.2. Top Ten Jurisdictions of CB Expansion Patents
    • 4.5.3. Legal Status of Cord Blood Expansion Patents
    • 4.5.4. Top Ten Inventors of Cord Blood Expansion Patents
    • 4.5.5. Top 20 Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

  • 5.1. Number of Papers Published on Umbilical Cord Blood
  • 5.2. Scientific Publications on Cord Tissue
  • 5.3. Scientific Publications on Placental Tissue
  • 5.4. Scientific Publications on UCB Cell Expansion

6. CLINICAL TRIAL: CORD BLOOD, CORD TISSUE, PLACENTA AND CB EXPANSION

  • 6.1. Clinical Trials involving Cord Blood Stem Cells
    • 6.1.1. Number of Clinical Trials using Cord Blood Stem Cells by Geography
    • 6.1.2. Number of Cord Blood Clinical Trials by Study Type
    • 6.1.3. Number of Clinical Trials by Phase of Study
    • 6.1.4. Number of Clinical Trials by Funder Type
    • 6.1.5. Diseases Addressed by Currently Recruiting Cord Blood Clinical Trials
    • 6.1.6. Companies Participating in Cord Blood Clinical Trials
  • 6.2. Clinical Trials Using Umbilical Cord Tissue
    • 6.2.1. Number of Clinical Trials using Cord Tissue by Region
    • 6.2.2. Number of Umbilical Cord Tissue Clinical Trials by Phase of Study
    • 6.2.3. Number of Cord Tissue Clinical Trials by Funder Type
    • 6.2.4. Commercial Entities in Umbilical Cord Tissue Clinical Trials
  • 6.3. Clinical Trials using Placental Tissue Stem Cells
    • 6.3.1. Number of Placental Tissue Clinical Trials by Phase of Study
  • 6.4. Clinical Trials of Expanded Cord Blood
    • 6.4.1. Major Participants in Clinical Trials using Expanded Cord Blood Cells

7. CORD BLOOD PROCESSING TECHNOLOGIES: AN OVERVIEW

  • 7.1. The Process of Separation of Cord Blood Stem Cells
    • 7.1.1. PrepaCyte CB
      • 7.1.1.1. Advantages of PrepaCyte-CB
      • 7.1.1.2. Treatment Outcomes with PrepaCyte-CB
    • 7.1.2. Hetastarch (HES)
    • 7.1.3. AutoXpress (AXP)
    • 7.1.4. SEPAX
    • 7.1.5. Plasma Depletion Method (MaxCell Process)
    • 7.1.6. Density Gradient Method
  • 7.2. Comparative Merits of Different Processing Methods
    • 7.2.1. Early Stage HSC Recovery by Technologies
    • 7.2.2. Mid Stage HSC (CD34+/CD133+) Recovery from CB by Technologies
    • 7.2.3. Late Stage Recovery of HSC from Cord Blood by Technologies
    • 7.2.4. HSC (CD45+) Recovery
  • 7.3. Days to Neutrophil Engraftment by Technologies
  • 7.4. Anticoagulants used in Cord Blood Processing
    • 7.4.1. Type of Anticoagulant and Cell Recovery Volume
  • 7.5. Percent Cell Recovery by Sample Size
  • 7.6. TNC Viability by Time Taken for Transport and Type of Anticoagulant
  • 7.7. Cryopreservation of Cord Blood Cells
    • 7.7.1. Ideal Cryoprotectants
  • 7.8. Bioprocessing of Umbilical Cord Tissue (UCT)
  • 7.9. Cord Blood Expansion Technologies
    • 7.9.1. Notch Ligand Delta 1
    • 7.9.2. Co-Culture with MSCs
    • 7.9.3. Copper Chelation
    • 7.9.4. Nicotinamide
    • 7.9.5. StemRegenin 1 (SR1)
    • 7.9.6. UM171
    • 7.9.7. Augmentation of Homing
    • 7.9.8. Prostaglandin E2
    • 7.9.9. Complement 3a (C3a)
    • 7.9.10. Fucosylation

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

  • 8.1. Number of Allogeneic CBU Donors and CBUs Available Worldwide
  • 8.2. HLA Typing of Worldwide Unrelated CB Donors and CBUs in 2021
  • 8.3. Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • 8.4. Global Exchange of Cord HSCs

9. INDICATIONS FOR UMBILICAL CORD BLOOD TRANSPLANTATION

  • 9.1. Beneficial Properties of Cord Blood Stem Cells
    • 9.1.1. Hematopoietic Properties of UCBCs
    • 9.1.2. Immune Properties of UCBCs
    • 9.1.3. Impact of HLA mismatch in UCBT Recipients
  • 9.2. Malignant Indications for UCB Transplantation
  • 9.3. Non-Malignant Diseases Treated by UCB Transplantation
  • 9.4. Diseases being Studied using UCB as Regenerative Medicine

10. CORD BLOOD: AS A TRANSPLANT MEDICINE

  • 10.1. Numbers of CB, BM and PB Stem Cell Transplantations Compared
  • 10.2. Cord Blood Stem Cells Transplantation by Geography, 1999-2021
    • 10.2.1. Indications for Hematopoietic Stem Cell Transplants (HSCTs) in the U.S.
      • 10.2.1.1. Top Five Indications for HCT in the U.S.
      • 10.2.1.2. Trends in Allogeneic HCTs in the U.S., by Recipient Age
      • 10.2.1.3. Trends in the Autologous HCT in the U.S. by Recipient Age
      • 10.2.1.4. HCTs by Cell Source in Adult Patients in the U.S.
      • 10.2.1.5. HCTs by Cell Source in less than 18 Patients in the U.S.
      • 10.2.1.6. Trends in the Use of Cord Blood HCTs in Adult & less than 18 Patients in the U.S.
      • 10.2.1.7. Number of Allogeneic CB HCTs in the U.S. by Race
      • 10.2.1.8. Number of HCTs Performed in the U.S. by Cell Source and Donor Type
      • 10.2.1.9. Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
      • 10.2.1.10. Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
    • 10.2.2. Ethnic Background and Cord Blood HLA Matching in the U.S.
    • 10.2.3. Cost of Cord Blood Transplantation
    • 10.2.4. Complications through 1-Year Post HCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

  • 11.1. Autism
  • 11.2. Cerebral Palsy
  • 11.3. Alzheimer's Disease
  • 11.4. Diabetes
  • 11.5. Heart Diseases
  • 11.6. Multiple Sclerosis
  • 11.7. Stroke

12. MARKET ANALYSIS

  • 12.1. Cord Blood Banking Services Market
    • 12.1.1. Share of Cord Blood Banking Service Market Revenue by Geography
    • 12.1.2. Public vs. Private Cord Blood Banking Service Market
    • 12.1.3. Global Market Share for Cord Blood and Cord Tissue Servicing
  • 12.2. Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue
    • 12.2.1. Market Share for CB Transplantation and CB for Regenerative Medicine
    • 12.2.2. Percent Share of Cord Blood & Cord Tissue Market by Indication
  • 12.3. Global Market for Umbilical Cord Tissue (UCT)

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

  • 13.1. AllCells
    • 13.1.1. Research Use Only (RUO) Products
      • 13.1.1.1. Mobilized Leukopak
      • 13.1.1.2. Leukopak
      • 13.1.1.3. Bone Marrow
      • 13.1.1.4. Cord Blood
      • 13.1.1.5. Whole Blood
    • 13.1.2. GMP Products
      • 13.1.2.1. Clinical Grade Mobilized Leukopak
      • 13.1.2.2. Clinical Grade Leukopak
      • 13.1.2.3. Clinical Grade Bone Marrow
    • 13.1.3. Isolated Cell Products
      • 13.1.3.1. CD34+ HSPCs
      • 13.1.3.2. T Cells
      • 13.1.3.3. NK Cells
      • 13.1.3.4. Monocytes
      • 13.1.3.5. B Cells
      • 13.1.3.6. PBMCs (MNCs)
  • 13.2. AlphaCord
    • 13.2.1. Prices
  • 13.3. Americord Registry, Inc.
    • 13.3.1. Cord Blood 2.0
    • 13.3.2. Cord Tissue with CryoMax Processing
    • 13.3.3. Placental Tissue with CryoMax processing
  • 13.4. Angiocrine Bioscience
    • 13.4.1. Proprietary E-CEL Platform
  • 13.5. Anja Health Personalized Cord Blood Banking
  • 13.6. Anthony Nolan
    • 13.6.1. Anthony Nolan Grant
  • 13.7. Baylx, Inc.
    • 13.7.1. Product Pipeline
  • 13.8. Be The Match
    • 13.8.1. Hub of Transplant Network
    • 13.8.2. Partners of Be The Match
    • 13.8.3. Allogeneic Cell Sources in Be The Match Registry
    • 13.8.4. Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
    • 13.8.5. Growth of Cord Blood Units on Be The Match Registry
    • 13.8.6. Diversity of CBUs in Be The Match Registry
  • 13.9. Biocell Center
  • 13.10. BioEden
    • 13.10.1. Dental Pulp Cells
    • 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
  • 13.11. BioIntegrate, LLC
  • 13.12. Bloodworks Northwest
    • 13.12.1. Products & Services
  • 13.13. California Umbilical Cord Collection Program
    • 13.13.1. Participating Locations
  • 13.14. Carolinas Cord Blood Bank (CCBB)
  • 13.15. Celaid Therapeutics
    • 13.15.1. In Vitro Expansion Technology
    • 13.15.2. Business Model
  • 13.16. Celebration Stem Cell Centre (CSCC)
    • 13.16.1. Products
  • 13.17. Cell Care
  • 13.18. Cellenkos, Inc.
    • 13.18.1. Technology
    • 13.18.2. Cellenkos' Pipeline
  • 13.19. Cells4Life Group LLP
    • 13.19.1. Cellsplus
    • 13.19.2. TotiCyte Processing Technology
    • 13.19.3. Cord Blood Releases from Cells4Life
  • 13.20. CellSave Arabia
    • 13.20.1. Cord Blood Stem Cell Banking Services
    • 13.20.2. Stem Cell Banking Price
  • 13.21. Celularity, Inc.
  • 13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
  • 13.23. CHOC Blood Bank
  • 13.24. Cleveland Cord Blood Center
    • 13.24.1. Research on Diabetic Retinopathy
    • 13.24.2. Research on Type I Diabetes
    • 13.24.3. Research on Parkinson's disease
    • 13.24.4. Research on Wound Healing
  • 13.25. ClinImmune Cell and Gene Therapy
    • 13.25.1. FDA Licensed Cord Blood
    • 13.25.2. Gene Therapy
    • 13.25.3. Cellular Therapies
  • 13.26. Cord Blood Bank of Arkansas (CBBA)
  • 13.27. Cord Blood Center Group
    • 13.27.1. Cord Blood Units Released form Cord Blood Center Group
  • 13.28. Cord Blood Registry (CBR)
    • 13.28.1. Business Experience
    • 13.28.2. Licensing & Accreditation
    • 13.28.3. Pricing
  • 13.29. Cord for Life
    • 13.29.1. Technology: PremierMax
  • 13.30. CordLife Group, Ltd.
    • 13.30.1. Accreditations & Certifications
    • 13.30.2. Services
    • 13.30.3. Releases from CordLife
    • 13.30.4. Revenue Generation by CordLife Group
  • 13.31. CordVida
  • 13.32. Crioestaminal
    • 13.32.1. Cord Blood Transplantation in Portugal
  • 13.33. Cryo-Cell International, Inc.
    • 13.33.1. Processing Technology
    • 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
    • 13.33.3. Cryo-Cell International's Revenue Generation
    • 13.33.4. Cryo-Cell International's Pricing
  • 13.34. CryoCyte, LLC
  • 13.35. CryoHoldco LATAM
  • 13.36. Cryopoint
  • 13.37. Cryoviva Biotech Pvt., Ltd.
  • 13.38. DKMS gGMBH
    • 13.38.1. Cord Blood Units
    • 13.38.2. Services
    • 13.38.3. DKMS' Donor Typing Profile & Active Donors
  • 13.39. Duke University School of Medicine
    • 13.39.1. Ducord (HPC Cord Blood)
  • 13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
    • 13.40.1. EBMT Transplant Activity
  • 13.41. Ever Supreme Bio Technology, Co., Ltd.
    • 13.41.1. Allogeneic UMSC01
    • 13.41.2. New Research
  • 13.42. ExCellThera
    • 13.42.1. ECT-001 Cell Therapy
  • 13.43. FamiCord Group
  • 13.44. Fate Therapeutics, Inc.
    • 13.44.1. FT1050 - Stem Cell Modulator
  • 13.45. Future Health
    • 13.45.1. Locations of Laboratories
    • 13.45.2. Business Experience
    • 13.45.3. Collection Kit
    • 13.45.4. Transportation Container
    • 13.45.5. Processing Method
    • 13.45.6. Components Stored
    • 13.45.7. Storage Methods
    • 13.45.8. Licensing & Accreditation
    • 13.45.9. Prices
    • 13.45.10. Additional Services
  • 13.46. Gamida Cell
    • 13.46.1. OMIDUBICELL
  • 13.47. GeneCell
  • 13.48. Global Cord Blood Corporation (GCBC)
    • 13.48.1. GCBC's Revenue Generation
  • 13.49. Glycostem Therapeutics
    • 13.49.1. Science and Technology
    • 13.49.2. oNKord
    • 13.49.3. viveNK
    • 13.49.4. uNiK Production Process
  • 13.50. Hawaii Cord Blood Bank
  • 13.51. HealthBaby
    • 13.51.1. Service Plans
    • 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
    • 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
    • 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
  • 13.52. HealthBanksUSA
    • 13.52.1. BioArchive Cryogenic Storage System
    • 13.52.2. AXP Cord Blood Processing
  • 13.53. HEMAFUND
  • 13.54. Hemogenyx Pharmaceuticals
    • 13.54.1. Technology
  • 13.55. IMMUNIQUE
  • 13.56. Insception LifeBank
    • 13.56.1. Cord Blood Releases from Insception LifeBank
    • 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
  • 13.57. JP McCarthy Cord Stem Cell Bank
  • 13.58. Kangstem Biotech, Co., Ltd.
    • 13.58.1. GD11 Brand
    • 13.58.2. Core Technology
  • 13.59. LifebankUSA
  • 13.60. LifeCell International Pvt. Ltd.
  • 13.61. Life Line Stem Cell
  • 13.62. LifeSouth Cord Blood Bank
    • 13.62.1. Accreditation & Hospital Partners
  • 13.63. Magenta Therapeutics
    • 13.63.1. Magenta's Cord Blood-Based Clinical Trial
  • 13.64. Maze Cord Blood
  • 13.65. Medipost, Co., Ltd.
    • 13.65.1. Medipost's Product & Products in Development
      • 13.65.1.1. CARTISTEM
      • 13.65.1.2. PNEUMOSTEM
      • 13.65.1.3. SMUP-IA-01
  • 13.66. Mesoblast, Ltd.
  • 13.67. MD Anderson Cord Blood Bank
  • 13.68. Mesoblast, Ltd.
    • 13.68.1. Mesoblast's UCB-Based Clinical Trial
  • 13.69. MiracleCord, Inc.
    • 13.69.1. AXP II Automated Processing
    • 13.69.2. StemCare Collection Kit
    • 13.69.3. Cost of Cord Blood Banking
  • 13.70. Mononuclear Therapeutics, Ltd.
    • 13.70.1. MonoTx Cord Blood Bank
    • 13.70.2. MonoTx's Pipeline
    • 13.70.3. Products
      • 13.70.3.1. Human Cord Blood Mononuclear Cells (MNCs)
      • 13.70.3.2. Exosome Rich Plasma (ERP)
      • 13.70.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
  • 13.71. New England Cord Blood Bank, Inc.
    • 13.71.1. Cord Blood Processing
    • 13.71.2. Cord Blood & Tissue Storage
  • 13.72. New York Blood Center
    • 13.72.1. Blood Products & Services
    • 13.72.2. Cell Therapies
    • 13.72.3. Cord Blood
  • 13.73. OrganaBio
    • 13.73.1. OrganaBio's Proprietary Supply Chains
    • 13.73.2. Perenatal Tissues
  • 13.74. PacifiCord
    • 13.74.1. FDA-Approved Sterile Collection Bags
    • 13.74.2. AXP Processing System
    • 13.74.3. BioArchive System
  • 13.75. Plasticell Ltd.
    • 13.75.1. CombiCult Technology
    • 13.75.2. Hematopoietic Stem Cell Expansion
  • 13.76. ReeLabs Pvt. Ltd.
  • 13.77. Restem, LLC
    • 13.77.1. Clinical Trial for COVID-19
    • 13.77.2. Clinical Trial for Muscular Dystrophy
    • 13.77.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
    • 13.77.4. Clinical Trial for Heart Failure
  • 13.78. San Diego Cord Blood Bank
  • 13.79. Saneron CCEL Therapeutics, Inc.
    • 13.79.1. U-CORD-CELL Program
    • 13.79.2. SERT-CELL Program
  • 13.80. SmartCells
  • 13.81. SSM Cardinal Glennon Children's Medical Center
    • 13.81.1. ALLOCORD
  • 13.82. Stembanc, Inc.
    • 13.82.1. Popular Packages from Stembanc
  • 13.83. Stem Cell Cryobank, Inc.
  • 13.84. StemCyte, Inc.
    • 13.84.1. Services
    • 13.84.2. Add On Services
    • 13.84.3. StemCyte in Clinical Trials
    • 13.84.4. StemCyte's Plans & Pricing
  • 13.85. Throne Biotechnologies, Inc.
    • 13.85.1. Effects of CB-SCs in Diabetics
    • 13.85.2. Effects of CB-SCs on Alopecia Areata
  • 13.86. Transcell Biolife
    • 13.86.1. ScellCare
    • 13.86.2. ToothScell
  • 13.87. Upstate Cord Blood Bank
  • 13.88. ViaCord
    • 13.88.1. ViaCord's Complete Services
    • 13.88.2. Cord Blood + Tissue Banking
    • 13.88.3. Newborn Digestive Health
    • 13.88.4. Newborn DNA Guardian
  • 13.89. Versity, Inc.
  • 13.90. Vita 34 AG
    • 13.90.1. Revenue Generation by Vita 34 AG
  • 13.91. Vitalant Clinical Services
    • 13.91.1. Hospital Services
    • 13.91.2. Laboratory Services
    • 13.91.3. Research
  • 13.92. World Marrow Donor Association (WMDA)
    • 13.92.1. WMDA Search & Match Service
  • 13.93. Worldwide Network for Blood & Marrow Transplantation (WBMT)

INDEX OF FIGURES

  • FIGURE 2.1: Parts of an Umbilical Cord
  • FIGURE 2.2: Percent Utilizations of BM-HSCs, PB-HSCs and CB-HSCs in Transplantations
  • FIGURE 2.3: Components of a Cord Blood Sample
  • FIGURE 2.4: Top Seven U.S. Private Cord Blood Banks by Size of Inventory
  • FIGURE 2.5: Cord Blood Revenues for Four Major Private Banks, 2017 to Present
  • FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.
  • FIGURE 2.7: % Share of Parents Storing CBUs in Private/Public Banks by Country/Region
  • FIGURE 4.1: Legal Status of Cord Blood Patents
  • FIGURE 4.2: Umbilical Cord Blood Patent Applications by Year, 2000 to Present
  • FIGURE 4.3: Umbilical Cord Blood Patent Application by Jurisdiction
  • FIGURE 4.4: Legal Status of Cord Blood Patents
  • FIGURE 4.5: UCB-Derived MSC Patent Applications by Year, 2000 to Present
  • FIGURE 4.6: UCB-Derived MSC Patent Application by Jurisdiction
  • FIGURE 4.7: Legal Status of Cord Tissue Patents
  • FIGURE 4.8: Umbilical Cord Patent Applications by Year, 2000 to Present
  • FIGURE 4.9: Placental Tissue
  • FIGURE 4.10: Placental Tissue Patent Applications by Year, 2000 to Present
  • FIGURE 4.11: Number of Cord Blood Expansion Patent Applications, 2000 to Present
  • FIGURE 5.1: Number of Published Papers on UCB according to PubMed.gov, 2000 to Present..
  • FIGURE 5.2: Number of Publications on Umbilical Cord Tissue, 2000 to Present
  • FIGURE 5.3: Number of Publications on Placental Tissue
  • FIGURE 5.4: Number of Scientific Publications on UCB Cell Expansion, 2000 to Present
  • FIGURE 6.1: Number of Cord Blood Clinical Trials by Geography
  • FIGURE 6.2: Number of Cord Blood Clinical Trials by Study Type
  • FIGURE 6.3: Number of Cord Blood Clinical Trials by Phase of Study
  • FIGURE 6.4: Number of Cord Blood Clinical Trials by Funder Type
  • FIGURE 6.5: Major Indications Addressed by Currently Recruiting Clinical Trials
  • FIGURE 6.6: Number of Clinical Trials using Cord Tissue by Region/Country
  • FIGURE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
  • FIGURE 6.8: Number of Cord Blood Clinical Trials by Funder Type
  • FIGURE 7.1: Separation of Buffy Layer
  • FIGURE 7.2: PrepaCyte-CB
  • FIGURE 7.3: Hetastarch (HES)
  • FIGURE 7.4: AutoXpress II
  • FIGURE 7.5: SEPAX 2
  • FIGURE 7.6: Plasma Depletion (PD) Method (MaxCell Process)
  • FIGURE 7.7: Density Gradient Separation of Cord Blood
  • FIGURE 7.8: Early Stage HSC Recovery from Cord Blood by Technologies
  • FIGURE 7.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
  • FIGURE 7.10: Late Stage Recovery of HSC from Cord Blood by Technologies
  • FIGURE 7.11: HSC (CD45+) Recovery Post Process from CB by Technologies
  • FIGURE 7.12: Days to Neutrophil Engraftment by Technologies
  • FIGURE 7.13: Differences in TNC Recovery among Anticoagulants
  • FIGURE 7.14: Type of Anticoagulant and Cell Recovery Volume
  • FIGURE 7.15: Percent Cell Recovery by Sample Size
  • FIGURE 7.16: TNC Viability by Time Taken for Transport
  • FIGURE 7.17: Difference in Recovery of VIABLE TNC after Thawing
  • FIGURE 7.18: CD34+ Cell Count CFU and Cell Apoptosis by Cryoprotectants
  • FIGURE 8.1: HLA Typing of Worldwide Unrelated CB Donors and CBUs
  • FIGURE 8.2: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • FIGURE 8.3: Global Exchange of Cord HSCs
  • FIGURE 9.1: Percent Utilization of PB, BM and CB in Transplantations Worldwide
  • FIGURE 10.1: CB, BM and PB Stem Cell Transplantations Compared, 1997-2021
  • FIGURE 10.2: Cord Blood Stem Cells Transplantation by Geography, 1999 to Present
  • FIGURE 10.3: Major Five Indications for HCT in the U.S.
  • FIGURE 10.4: Trends in Allogeneic HCTs in the U.S., by Recipient Age
  • FIGURE 10.5: Trends in the Autologous HCT in the U.S. by Recipient Age
  • FIGURE 10.6: HCTs by Cell Source in Adult Patients in the U.S.
  • FIGURE 10.7: HCTs by Cell Source in less than 18 Patients in the U.S.
  • FIGURE 10.8: Trends in the Use of CB HCTs in greater than or equal to 18 & less than 18 Patients in the U.S.
  • FIGURE 10.9: Number of Allogeneic CB HCTs in the U.S. by Race
  • FIGURE 10.10: Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
  • FIGURE 10.11: Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
  • FIGURE 12.1: Global Cord Blood Banking Service Market, 2022-2030
  • FIGURE 12.2: % Share of Cord Blood Banking Service Market Revenue by Geography
  • FIGURE 12.3: Global Cord Blood Banking Service Market, Public vs. Private
  • FIGURE 12.4: Global CB Banking Service Market Share for Cord Blood and Cord Tissue
  • FIGURE 12.5: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
  • FIGURE 12.6: Use of Umbilical Cord Blood in Transplantation vs. Regenerative Medicine
  • FIGURE 12.7: Percent Share of Umbilical Cord Blood and Tissue Utilization by Indication
  • FIGURE 13.1: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
  • FIGURE 13.2: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
  • FIGURE 13.3: Growth of CBUs on Be The Match Registry, 2001 to Present
  • FIGURE 13.4: Diversity of CBUs in Be The Match Registry
  • FIGURE 13.5: Funders for CIBMTR in 2022
  • FIGURE 13.6: Sales Revenues and Gross Profits for CordLife, 2014-2021
  • FIGURE 13.7: Cryo-Cell International's Revenue Generation, 2017-2022
  • FIGURE 13.8: GCBC's Revenue Generation, 2015-2022
  • FIGURE 13.9: Revenue Generation by Vita 34 AG, 2014-2021

INDEX OF TABLES

  • TABLE 2.1: An Overview of Public Cord Blood Banks
  • TABLE 2.2: Public Cord Blood Banks in the U.S.
  • TABLE 2.3: Public Cord Blood Banks in Major European Countries
  • TABLE 2.4: International Prices of a Cord Blood Unit (CBU)
  • TABLE 2.5: Prices of CBUs in National Marrow Donor Program (NMDP) Banks in the U.S.
  • TABLE 2.6: An Overview of Private Cord Blood Banks
  • TABLE 2.7: The Leading Private Cord Blood Banks in the U.S.
  • TABLE 2.9: Pricing for Storage in Commercial Cord Blood Banks
  • TABLE 2.10: Leading Private CB Banks by their Inventory Size and Geographic Location
  • TABLE 2.11: World's Largest Private Cord Blood Bank Operators by Inventory
  • TABLE 2.12: Cord Blood Revenues for Four Major Private Banks - 2017 to Present
  • TABLE 2.13: Comparison of Public, Private and Hybrid Cord Blood Banks
  • TABLE 3.1: AABB-Accredited Cord Blood Banks
  • TABLE 3.2: Select FACT-Accredited Cord Blood Banks
  • TABLE 4.1: Umbilical Cord Blood Patent Application by Jurisdiction
  • TABLE 4.2: Top Ten Umbilical Cord Blood Patent Applicants
  • TABLE 4.3: Top Ten Inventors of Umbilical Cord Blood Patents
  • TABLE 4.4: Top Twenty Owners of Umbilical Cord Blood Patents
  • TABLE 4.5: UCB-Derived MSC Patent Applications by Jurisdiction
  • TABLE 4.6: Top Ten UCB-Derived MSC Patent Applicants
  • TABLE 4.7: Top Ten Inventors of UCB-Derived MSC Patents
  • TABLE 4.8: Top Twenty Owners of UCB-Derived MSC Patents
  • TABLE 4.9: Cord Tissue Patent Application by Jurisdiction
  • TABLE 4.10: Top Ten Wharton's Jelly Patent Applicants
  • TABLE 4.11: Top Ten Inventors of Cord Tissue Patents
  • TABLE 4.12: Top Twenty Owners of Cord Tissue Patents
  • TABLE 4.13: Top Ten Applicants of Placental Tissue Patents
  • TABLE 4.14: Top Ten Jurisdictions of Placental Tissue Patents
  • TABLE 4.15: Top Ten Inventors of Placental Tissue Patents
  • TABLE 4.16: Top Twenty Owners of Placental Tissue Patents
  • TABLE 4.17: Legal Status of Placental Tissue Patents
  • TABLE 4.18: Top Ten Jurisdictions of CB Expansion Patents
  • TABLE 4.19: Legal Status of Cord Blood Expansion Patents
  • TABLE 4.20: Top Ten Inventors of Cord Blood Expansion Patents
  • TABLE 4.21: Top Twenty Owners of Placental Tissue Patents
  • TABLE 6.1: Total Number of Umbilical Cord-Related Clinical Studies
  • TABLE 6.2: Number of Cord Blood Clinical Trials by Geography
  • TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type
  • TABLE 6.4: Number of Cord Blood Clinical Trials by Phase of Study
  • TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type
  • TABLE 6.6: List of Select Companies Participating in Cord Blood Clinical Trials
  • TABLE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
  • TABLE 6.8: Number of Cord Tissue Clinical Trials by Funder Type
  • TABLE 6.9: Select Commercial Entities in Umbilical Cord Tissue Clinical Trials
  • TABLE 6.10: Number of Placental Tissue Clinical Trials by Phase of Study
  • TABLE 6.11: Major Industry Participants using Expanded Cord Blood in Clinical Trials
  • TABLE 7.1: Advantages of PrepaCyte-CB
  • TABLE 7.2: Treatment Outcomes with PrepaCyte-CB
  • TABLE 7.3: Cord Blood Expansion Approaches in Ongoing Clinical Trials
  • TABLE 8.1: Cord Blood Units Registered with WMDA Registry
  • TABLE 8.2: Number of Unrelated CB Donors and CBUs available Worldwide
  • TABLE 8.3: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
  • TABLE 9.1: Malignant Diseases Treated by UCB Transplantation
  • TABLE 9.2: Non-Malignant Diseases Treated by UCB Transplantation
  • TABLE 9.3: Diseases being studied using UCB as Regenerative Medicine
  • TABLE 10.1: Numbers of CB, BM and PB Stem Cell Transplantations Compared by Year
  • TABLE 10.2: Number of HCTs Performed in the U.S. by Disease as reported to CIBMTR
  • TABLE 10.3: Number of HCTs Performed in the U.S. by Cell Source and Donor Type
  • TABLE 10.4: Comparison of Median Costs during Transplant Admit
  • TABLE 10.5: Complications Post HCT in UCB vs. MRD BM/PBSC vs. MURD BM/PBSC
  • TABLE 11.1: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Autism
  • TABLE 11.2: Trials Evaluating the Effect of Cord Blood Stem Cells on Cerebral Palsy
  • TABLE 11.3: Clinical Trials Studying the Effect of CBU on Alzheimer's Disease
  • TABLE 11.4: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Diabetes
  • TABLE 11.5: Trials Evaluating the Effect of Cord Blood Stem Cells on Heart Diseases
  • TABLE 11.6: Clinical Trials Evaluating the Effect of UCB on Multiple Sclerosis
  • TABLE 11.7: Clinical Trials Evaluating the Effect of UCB on Stroke
  • TABLE 12.1: Global Cord Blood Banking Service Market, 2022-2030
  • TABLE 12.2: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
  • TABLE 13.1: Angiocrine's R&D Pipeline
  • TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
  • TABLE 13.3: Growth of Cord Blood Units in Be The Match Registry by Year
  • TABLE 13.4: Diversity of CBUs in Be The Match Registry
  • TABLE 13.5: Cell Care's Pricing for Cord Blood Processing and Storage
  • TABLE 13.6: Cellenkos' Product Pipeline
  • TABLE 13.7: Cord Blood Releases from Cells4Life
  • TABLE 13.8: Celularity's Active Clinical Pipeline
  • TABLE 13.9: Cord Blood Unitts Released from Cord Blood Center Group by Year
  • TABLE 13.10: Cord Blood and Cord Tissue Units Released from CordLife
  • TABLE 13.11: Recovery of Viable CFU by PrepaCyte-CB
  • TABLE 13.12: Cryo-Cell International's Revenue Generation, 2017 to Present
  • TABLE 13.13: Cryo-Cell International's Pricing
  • TABLE 13.14: CryoCyte's Option Plans & Pricing
  • TABLE 13.15: DKMS' Donor Typing Profile & Active Donors
  • TABLE 13.16: Allogeneic and Autologous infusions by Indication Reported by EBMT
  • TABLE 13.17: Cord Blood Banking Cost in GeneCell
  • TABLE 13.18: GCBC's Revenue Generation, 2015 to Present
  • TABLE 13.19: Glycostem's Product Pipeline
  • TABLE 13.20: Insception LifeBank's Pricing
  • TABLE 13.21: Cord Blood Releases from Insception LifeBank for Transplantation
  • TABLE 13.22: Cord Blood Cells Released for Regenerative Medicine from Insception
  • TABLE 13.23: Kangstem's Sponsor Initiated Clinical Trials
  • TABLE 13.24: LifeCell International's Pricing
  • TABLE 13.25: Maze Cord Blood: Banking Cost
  • TABLE 13.26: MiracleCord's Cord Blood Banking Cost
  • TABLE 13.27: MonoTx's Product Pipeline